ABSI on Nasdaq
Absci Corp
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with iSpecimen Inc., VITASPRING BIOMEDICAL CO. LTD. or OneMedNet Corp, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-4297.0%Operating margin3
-4113.7%Net margin3
-38.2%Revenue growth, 20253
-60.8%Return on equity3
-$94.0MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development70¢$81.4M
- Selling, general and admin30¢$35.1M
- Income tax0¢$69.0K
Out of $2.8M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Partner program revenue | $2.8M | $4.5M |
| Research and development | $81.4M | $63.9M |
| Selling, general and administrative | $35.1M | $36.2M |
| Depreciation and amortization | $11.7M | $13.4M |
| Gain on settlement of contingent consideration | -$5.1M | $0 |
| Total operating expenses | $123.1M | $113.4M |
| Operating loss | -$120.3M | -$108.9M |
| Interest expense | -$209.0K | -$565.0K |
| Other income, net | $5.4M | $6.4M |
| Total other income, net | $5.2M | $5.9M |
| Loss before income taxes | -$115.1M | -$103.0M |
| Income tax expense | -$69.0K | -$70.0K |
| Net loss | -$115.2M | -$103.1M |
| Net loss per share: basic (in usd per share) | -$0.84 | -$0.94 |
| Net loss per share: diluted (in usd per share) | -$0.84 | -$0.94 |
| Weighted-average common shares outstanding: basic (in shares) | 136.8M shares | 110.2M shares |
| Weighted-average common shares outstanding: diluted (in shares) | 136.8M shares | 110.2M shares |
| Foreign currency translation adjustments | $448.0K | -$26.0K |
| Unrealized gain on marketable securities | $147.0K | $59.0K |
| Comprehensive loss | -$114.6M | -$103.1M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $20.0M | $41.2M | |
| Restricted cash | $0 | $15.9M | |
| Marketable securities | $124.3M | $71.2M | |
| Prepaid expenses and other current assets | $5.3M | $5.5M | |
| Total current assets | $149.6M | $133.8M | |
| Operating lease right-of-use assets | $2.9M | $4.0M | |
| Property and equipment, net | $20.9M | $29.2M | |
| Intangibles, net | $41.5M | $44.9M | |
| Restricted cash, long-term | $1.1M | $1.1M | |
| Other long-term assets | $383.0K | $705.0K | |
| TOTAL ASSETS | $216.3M | $213.6M | |
| Accounts payable and accrued expenses | $19.3M | $10.4M | |
| Contingent consideration | $0 | $12.8M | |
| Long-term debt | $873.0K | $2.7M | |
| Operating lease obligations | $1.8M | $1.6M | |
| Deferred revenue | $739.0K | $1.1M | |
| Total current liabilities | $22.8M | $28.7M | |
| Long-term debt, net of current portion | $0 | $1.3M | |
| Operating lease obligations, net of current portion | $2.6M | $4.4M | |
| Deferred revenue, long-term | $436.0K | $0 | |
| Other long-term liabilities | $1.0M | $133.0K | |
| TOTAL LIABILITIES | $26.8M | $34.5M | |
| Preferred stock | $0 | $0 | |
| Common stock | $15.0K | $12.0K | |
| Additional paid-in capital | $813.6M | $688.7M | |
| Accumulated deficit | -$624.8M | -$509.6M | |
| Accumulated other comprehensive income (loss) | $591.0K | -$4.0K | |
| TOTAL STOCKHOLDERS' EQUITY | $189.4M | $179.1M | $176.2M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $216.3M | $213.6M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$115.2M | -$103.1M |
| Depreciation and amortization | $11.7M | $13.4M |
| Stock-based compensation | $18.3M | $19.5M |
| Accretion of discount on marketable securities | -$2.5M | -$3.7M |
| Gain on settlement of contingent consideration | -$5.1M | $0 |
| Other | -$584.0K | $2.0M |
| Accounts receivable, net | $0 | $2.2M |
| Prepaid expenses and other current assets | -$424.0K | -$484.0K |
| Operating lease right-of-use assets and liabilities | -$555.0K | -$762.0K |
| Other long-term assets | $249.0K | -$68.0K |
| Accounts payable and accrued expenses | $1.1M | $1.7M |
| Deferred revenue | $59.0K | -$3.0M |
| Net cash used in operating activities | -$92.9M | -$72.4M |
| Purchases of property and equipment | -$1.1M | -$404.0K |
| Investment in marketable securities | -$119.9M | -$186.1M |
| Proceeds from maturities of marketable securities | $69.5M | $144.0M |
| Proceeds from sales of property and equipment | $1.3M | $939.0K |
| Net cash used in investing activities | -$50.2M | -$41.6M |
| Principal payments on long-term debt | -$3.1M | -$3.4M |
| Principal payments on finance lease obligations | -$79.0K | -$643.0K |
| Proceeds from issuance of common stock, net | $105.8M | $82.4M |
| Proceeds from issuance of common stock through employee equity plans, net | $3.3M | $4.2M |
| Net cash provided by financing activities | $105.9M | $82.5M |
| Net decrease in cash, cash equivalents, and restricted cash | -$37.1M | -$31.5M |
| Cash paid during the period for interest | $178.0K | $561.0K |
| Right-of-use assets obtained in exchange for operating lease obligation | $0 | $433.0K |
| Payments on long-term debt by third-party through sale of equipment | $0 | $540.0K |
Former names
- AbSci, LLCApr 21, 2016 to Dec 19, 20192
Recent filings
- Oct 14, 20264
- Oct 14, 20264
- Oct 14, 20264
- Sep 1, 20264
- Aug 11, 20268-K
- Aug 11, 202610-Q
- Aug 7, 20263
- Aug 7, 20264
- Jul 6, 20264
- Jun 26, 20264
- Jun 24, 20268-K
- Jun 24, 2026424B5
- Jun 24, 20268-K
- Jun 15, 20264/A
- Jun 11, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAbsci Corp filings on SEC EDGAR
- 2SEC EDGARAbsci Corp filings on SEC EDGAR
- 3SEC EDGARAbsci Corp 10-K for fiscal 2025
- 4SEC EDGARAbsci Corp 10-K for fiscal 2020
- 5SEC EDGARAbsci Corp 10-K for fiscal 2021
- 6SEC EDGARAbsci Corp 10-K for fiscal 2022
- 7SEC EDGARAbsci Corp 10-K for fiscal 2023
- 8SEC EDGARAbsci Corp 10-Q for fiscal 2026
- 9SEC EDGARAbsci Corp 10-Q for fiscal 2026